Last week, readers were most interested in Labcorp's acquisition of assets from MAWD, a CE mark for Roche's mass spec system, and features on Volition and Siemens Healthineers.

Oncologists want definitive guidance on whether patients with resectable NSCLC benefit from immunotherapy before and after ...

Recent research bolsters the case that radiotherapy to treat primary endometrial cancer is associated with an increased risk ...

LUMINA is an Advanced Minimal Residual Disease Detection Platform for Lung Cancer Harnessing the Power of Multi-omics Biomarkers and AILOS ...